Compare TG Therapeutics Inc (TGTX) vs Western Digital Corp (WDC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Western Digital Corp — how do they compare? TG Therapeutics Inc trades at $55 (market cap $8.16B), while Western Digital Corp trades at $395.6 (market cap $147.23B). The key difference: Western Digital Corp is far larger — about 18× TG Therapeutics Inc's market cap, and Western Digital Corp pays a 0.15% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Western Digital Corp for 37 Days on average.
| TGTX | WDC | |
|---|---|---|
Market Cap | $8.16B | $147.23B |
Volume | 1,735,121 | 9,341,468 |
Sector | Health | Technology |
52-Week High | $59.06 | $746.23 |
52-Week Low | $26.94 | $113.13 |
Typical Hold Time | 16 Days | 37 Days |
Enterprise Value | $8.37B | $146.70B |
Dividend Yield | — | 0.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Western Digital (WDC) trades at $397.28, down 1.96% amid recent sector volatility. The stock shows strong fundamentals with a 14.61 P/E ratio and impressive 71.97% net income margin, supported by three consecutive quarterly earnings beats. Technical indicators suggest bearish momentum with the price near pivot point support at $397. Recent news highlights competitive pressures from Toshiba's planned HDD production expansion, contributing to the stock's recent decline.
WDC presents a compelling value opportunity with strong profitability metrics and analyst consensus favoring bullish sentiment (72% buy ratings). However, investors face near-term risks from increased competition in AI storage markets and potential margin pressure. The $647.58 consensus price target suggests significant upside potential if the company maintains its competitive positioning and executes on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Western Digital Corp
Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →
